Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJMSC in Knee Osteoarthrosis
NCT02963727Phase 1Unknown
- Start
- Jan 2017
- Primary completion
- Oct 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of wharton's jelly mesenchymal stromal cells in knee osteoarthritis (OA). Primary endpoint: Evaluation of the safety and tolerability of the intra articular injection at 6 months. Status: unknown.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02963727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963727.